Kiniksa Pharmaceuticals International Plc (KNSA) Return on Investment ROI from the first quarter of 2026 to first quarter of 2025 and for the year 2026, average high and low, overall ranking from Mar 31 2026 to Mar 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Kiniksa Pharmaceuticals International Plc  (NASDAQ: KNSA)


Kiniksa Pharmaceuticals International Plc's ROI from its first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Kiniksa Pharmaceuticals International Plc's ROI in the first quarter of 2026?
Kiniksa Pharmaceuticals International Plc achieved a return on average invested assets (ROI) of 12.05 % in its first quarter of 2026, this is above KNSA's average return on investment of -11.61%.
Kiniksa Pharmaceuticals International Plc invested over the 12 months ending in its first quarter of 2026 $606 million

ROI has improved compared to 10.45% in the fourth quarter of 2025, due to net income growth.

Within the Healthcare sector 33 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Mar 31 2026 quarter, so far to 269, from total ROI ranking in the fourth quarter of 2025 at 582.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Investment Change TTM 27.68 % 21.9 % 15.17 % 9.9 % 6.44 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 669 624 589 543 502
Return On Investment (TTM) 12.05 % 10.45 % 6.8 % 0.97 % -3.57 %
KNSA's Overall Ranking # 269 # 582 # 417 # 1939 # 2504
Seq. Investment Change TTM 7.38 % 6.84 % 6.52 % 4.48 % 2.51 %
Seq. Net Income Change TTM 23.82 % 64.28 % 649.85 % - -
Net Income (TTM) in Millions 73 59 36 5 -17

KNSA Company Profile >> Back to KNSA Roi Comparisons >> See Annual KNSA Return On Investment



Return On Investment KNSA's Ranking
Within: No.
Industry # 10
Sector # 34
Overall # 269

Return On Investment Statistics
High Average Low
62.52 %
-11.61 %
-68.47 %
(Dec 31 2022)   (Dec 31 2021)







Financial Statements
Kiniksa Pharmaceuticals International Plc's I. Quarter Investments $ 669 Millions KNSA's Balance sheet
Kiniksa Pharmaceuticals International Plc's I. Quarter Income $ 23 Millions Quarterly KNSA's Income Statement
KNSA's Income by Division See KNSA's Income by Division


KNSA Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 624 480 463 413 185
Y / Y Investment Growth 30.11 % 3.73 % 12.13 % 122.66 % -40.75 %
Net Income in Millions 59 -43 14 183 -158
Y / Y Net Income Growth - - -92.32 % - -
Annual Return On Investment 9.45 % -9 % 3.04 % 44.44 % -85.22 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 9.45 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
KNSA's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for KNSA's Competitors
Subscribers only: Roi for Kiniksa Pharmaceuticals International Plc's Suppliers
Subscribers only: Return On Investment for KNSA's Customers

Other Ratios
KNSA's Roa KNSA's Inventory Turnover Ratio KNSA's Growth Rates KNSA's Dividend Statistics
KNSA's Profitability Ratios KNSA's Asset Turnover Ratio KNSA's Dividend Growth
KNSA's Roe KNSA's Valuation Ratios KNSA's Financial Strength Ratios KNSA's Dividend Payout Ratio



Companies with similar Return On Investment at Mar 31 2026, within Healthcare Sector ROI
Adma Biologics Inc   30.38 %
Medpace Holdings Inc   30.34 %
Spero Therapeutics Inc   29.59 %
Rafael Holdings Inc  28.08 %
Incyte Corporation  27.50 %
Carlisle Companies Incorporated  24.39 %
Iradimed Corporation  23.59 %
Catalyst Pharmaceuticals Inc   23.58 %
Engene Therapeutics Inc   22.76 %
Protalix Biotherapeutics inc   22.70 %
Electromed Inc   22.36 %
Dexcom Inc   22.17 %
Illumina Inc   22.01 %
Pro dex Inc   20.88 %
Gilead Sciences Inc   20.52 %
Vertex Pharmaceuticals Inc  20.49 %
Agilent Technologies inc   20.46 %
Zoetis Inc   20.35 %
Resmed Inc   20.23 %
Soleno Therapeutics Inc  19.51 %
Krystal Biotech Inc   19.07 %
Puma Biotechnology Inc   18.83 %
United Therapeutics Corporation  18.64 %
Hca Healthcare Inc   18.54 %
Chemed Corporation  18.36 %
Apellis Pharmaceuticals Inc   17.94 %
Neurocrine Biosciences Inc   17.65 %
Halozyme Therapeutics Inc   17.53 %
Transmedics Group Inc   17.09 %
Inspire Medical Systems inc   16.60 %

Date modified: 2026-09-26T07:37:46+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.